{"id":969,"date":"2021-03-05T15:52:00","date_gmt":"2021-03-05T15:52:00","guid":{"rendered":"https:\/\/www.ub.edu\/creatio\/wp\/?post_type=actualitat&#038;p=969"},"modified":"2022-08-03T15:57:30","modified_gmt":"2022-08-03T15:57:30","slug":"car_t_ari_0001","status":"publish","type":"actualitat","link":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/","title":{"rendered":"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades)"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"659\" height=\"527\" data-src=\"https:\/\/www.ub.edu\/creatio\/wp\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\" alt=\"Sala Blanca_CAR-T ARI-0001_Ter\u00e0pies Avan\u00e7ades\" class=\"wp-image-970 lazyload\" data-srcset=\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png 659w, https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades-300x240.png 300w\" data-sizes=\"(max-width: 659px) 100vw, 659px\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 659px; --smush-placeholder-aspect-ratio: 659\/527;\" \/><noscript><img loading=\"lazy\" decoding=\"async\" width=\"659\" height=\"527\" src=\"https:\/\/www.ub.edu\/creatio\/wp\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\" alt=\"Sala Blanca_CAR-T ARI-0001_Ter\u00e0pies Avan\u00e7ades\" class=\"wp-image-970\" srcset=\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png 659w, https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades-300x240.png 300w\" sizes=\"(max-width: 659px) 100vw, 659px\" \/><\/noscript><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">El Centre per a la Producci\u00f3 i Validaci\u00f3 de Ter\u00e0pies Avan\u00e7ades de la Universitat de Barcelona ha participat en la producci\u00f3 dels virus que actuen com a vectors en el medicament CAR-T ARI-0001, aprovat per l\u2019Ag\u00e8ncia Espanyola de Medicaments i Productes Sanitaris (AEMPS) i desenvolupat per l\u2019Hospital Cl\u00ednic de Barcelona.<\/h3>\n\n\n\n<p>CAR-T ARI-0001 \u00e9s un tractament de c\u00e8l\u00b7lules amb receptor d\u2019antigen quim\u00e8ric (CAR-T, en les seves sigles en angl\u00e8s), un tipus de ter\u00e0pia cel\u00b7lular i g\u00e8nica en la qual el pacient es converteix en el seu propi donant gr\u00e0cies a la modificaci\u00f3 gen\u00e8tica dels seus limf\u00f2cits. \u00c9s el primer tractament d\u2019aquest tipus que s\u2019ha desenvolupat \u00edntegrament a Espanya, i tamb\u00e9 \u00e9s el primer del seu g\u00e8nere que s\u2019aprova a l\u2019Estat, a trav\u00e9s d\u2019una autoritzaci\u00f3 excepcional d\u2019\u00fas per part de l\u2019AEMPS.<\/p>\n\n\n\n<p>La modificaci\u00f3 gen\u00e8tica dels limf\u00f2cits propis del pacient \u00e9s un proc\u00e9s cr\u00edtic en el funcionament de les ter\u00e0pies CAR-T. Es duu a terme usant un producte intermedi basat en un virus que confereix als limf\u00f2cits la capacitat d\u2019atacar espec\u00edficament les c\u00e8l\u00b7lules tumorals. Respecte a la fabricaci\u00f3 d\u2019aquest virus en el cas de CAR-T ARI-0001, el director de Creatio, Josep M. Canals, explica que \u00abs\u2019ha fet seguint els protocols de l\u2019Hospital Cl\u00ednic a les instal\u00b7lacions de Creatio i segons les condicions d\u2019alta qualitat o bones pr\u00e0ctiques de producci\u00f3, conegudes com a GMP (good manufacturing practices), que certifica l\u2019AEMPS\u00bb.<\/p>\n\n\n\n<p>El l\u00edder del projecte, Manel Juan, cap del Servei d\u2019Immunologia al Centre de Diagn\u00f2stic Biom\u00e8dic (CDB) del Cl\u00ednic i professor del Departament de Biomedicina, subratlla que \u00ables GMP permeten acreditar la producci\u00f3 d\u2019aquest producte intermedi amb relativa facilitat, per\u00f2 sobretot cal remarcar que l\u2019aplicaci\u00f3 d\u2019aquestes normes ha garantit la qualitat i reproductibilitat d\u2019aquest producte intermedi, fet que ha estat clau per al producte cel\u00b7lular CAR-T ARI-0001\u00bb.<\/p>\n\n\n\n<p>Des de l\u2019any 2017, Creatio produeix els virus en condicions GMP per a l\u2019Hospital Cl\u00ednic de Barcelona. Actualment, est\u00e0 produint part\u00edcules virals que es distribueixen a quatre centres hospitalaris de l\u2019Estat: l\u2019Hospital Cl\u00ednic i l\u2019Hospital de Sant Pau i la Santa Creu (Barcelona), la Cl\u00ednica Universit\u00e0ria de Navarra i l\u2019Hospital Universitari La Paz (Madrid). Aquests virus s\u2019empraran per produir nous CAR-T com a medicaments avan\u00e7ats per a pacients que pateixen patologies hematol\u00f2giques.<\/p>\n\n\n\n<p>La leuc\u00e8mia limfobl\u00e0stica aguda (LLA) \u00e9s un dels quatre tipus principals de leuc\u00e8mia i es caracteritza per una producci\u00f3 excessiva de limf\u00f2cits, o gl\u00f2buls blancs, immadurs que es multipliquen de manera r\u00e0pida i desplacen les c\u00e8l\u00b7lules normals de la medul\u00b7la \u00f2ssia. Tot i que en la majoria dels casos s\u2019aconsegueix una remissi\u00f3 completa amb quimioter\u00e0pia o amb el trasplantament de medul\u00b7la, entre un 10 i un 15&nbsp;% dels pacients moren per resist\u00e8ncia al tractament, per la seva toxicitat o per una recaiguda. Els resultats de l\u2019assaig realitzat amb CAR-T ARI-0001 demostren que aquesta ter\u00e0pia produeix una resposta completa en m\u00e9s d\u2019un 70&nbsp;% dels pacients, \u00e9s a dir, que no queda malaltia residual en aquests casos.<\/p>\n\n\n\n<p>Enlla\u00e7 v\u00eddeo:&nbsp;<a href=\"https:\/\/www.ub.edu\/ubtv\/video\/creatio-participa-en-la-produccio-de-la-terapia-avancada-car-t-ari-0001\" target=\"_blank\" rel=\"noreferrer noopener\">Creatio participa en la producci\u00f3 de la ter\u00e0pia avan\u00e7ada CAR-T ARI-0001<\/a><\/p>\n","protected":false},"author":1,"featured_media":970,"template":"","acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio\" \/>\n<meta property=\"og:description\" content=\"El Centre per a la Producci\u00f3 i Validaci\u00f3 de Ter\u00e0pies Avan\u00e7ades de la Universitat de Barcelona ha participat en la producci\u00f3 dels virus que actuen com a vectors en el medicament CAR-T ARI-0001, aprovat per l\u2019Ag\u00e8ncia Espanyola de Medicaments i Productes Sanitaris (AEMPS) i desenvolupat per l\u2019Hospital Cl\u00ednic de Barcelona. CAR-T ARI-0001 \u00e9s un tractament [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/\" \/>\n<meta property=\"og:site_name\" content=\"Creatio\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-03T15:57:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\" \/>\n\t<meta property=\"og:image:width\" content=\"659\" \/>\n\t<meta property=\"og:image:height\" content=\"527\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Creatio_UB\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/\",\"url\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/\",\"name\":\"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio\",\"isPartOf\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\",\"datePublished\":\"2021-03-05T15:52:00+00:00\",\"dateModified\":\"2022-08-03T15:57:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage\",\"url\":\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\",\"contentUrl\":\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png\",\"width\":659,\"height\":527,\"caption\":\"Sala Blanca_CAR-T ARI-0001_Ter\u00e0pies Avan\u00e7ades\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.ub.edu\/creatio\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/#website\",\"url\":\"https:\/\/www.ub.edu\/creatio\/\",\"name\":\"Creatio\",\"description\":\"Production and validation center of advanced therapies\",\"publisher\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ub.edu\/creatio\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/#organization\",\"name\":\"Creatio\",\"url\":\"https:\/\/www.ub.edu\/creatio\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.ub.edu\/creatio\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2021\/12\/creatio-logo.png\",\"contentUrl\":\"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2021\/12\/creatio-logo.png\",\"width\":698,\"height\":110,\"caption\":\"Creatio\"},\"image\":{\"@id\":\"https:\/\/www.ub.edu\/creatio\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/Creatio_UB\",\"https:\/\/www.linkedin.com\/company\/creatio-ub\",\"https:\/\/www.instagram.com\/creatio.ub\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/","og_locale":"es_ES","og_type":"article","og_title":"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio","og_description":"El Centre per a la Producci\u00f3 i Validaci\u00f3 de Ter\u00e0pies Avan\u00e7ades de la Universitat de Barcelona ha participat en la producci\u00f3 dels virus que actuen com a vectors en el medicament CAR-T ARI-0001, aprovat per l\u2019Ag\u00e8ncia Espanyola de Medicaments i Productes Sanitaris (AEMPS) i desenvolupat per l\u2019Hospital Cl\u00ednic de Barcelona. CAR-T ARI-0001 \u00e9s un tractament [&hellip;]","og_url":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/","og_site_name":"Creatio","article_modified_time":"2022-08-03T15:57:30+00:00","og_image":[{"width":659,"height":527,"url":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Creatio_UB","twitter_misc":{"Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/","url":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/","name":"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades) - Creatio","isPartOf":{"@id":"https:\/\/www.ub.edu\/creatio\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage"},"image":{"@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png","datePublished":"2021-03-05T15:52:00+00:00","dateModified":"2022-08-03T15:57:30+00:00","breadcrumb":{"@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#primaryimage","url":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png","contentUrl":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2022\/08\/CAR-T-ARI-0001_Terapies-Avancades.png","width":659,"height":527,"caption":"Sala Blanca_CAR-T ARI-0001_Ter\u00e0pies Avan\u00e7ades"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ub.edu\/creatio\/actualitat\/car_t_ari_0001\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.ub.edu\/creatio\/"},{"@type":"ListItem","position":2,"name":"CAR-T ARI-0001 (Ter\u00e0pies Avan\u00e7ades)"}]},{"@type":"WebSite","@id":"https:\/\/www.ub.edu\/creatio\/#website","url":"https:\/\/www.ub.edu\/creatio\/","name":"Creatio","description":"Production and validation center of advanced therapies","publisher":{"@id":"https:\/\/www.ub.edu\/creatio\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ub.edu\/creatio\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.ub.edu\/creatio\/#organization","name":"Creatio","url":"https:\/\/www.ub.edu\/creatio\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.ub.edu\/creatio\/#\/schema\/logo\/image\/","url":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2021\/12\/creatio-logo.png","contentUrl":"https:\/\/www.ub.edu\/creatio\/wp-content\/uploads\/2021\/12\/creatio-logo.png","width":698,"height":110,"caption":"Creatio"},"image":{"@id":"https:\/\/www.ub.edu\/creatio\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Creatio_UB","https:\/\/www.linkedin.com\/company\/creatio-ub","https:\/\/www.instagram.com\/creatio.ub\/"]}]}},"lang":"ca","translations":{"ca":969,"es":971,"en":973},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/actualitat\/969"}],"collection":[{"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/actualitat"}],"about":[{"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/types\/actualitat"}],"author":[{"embeddable":true,"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/media\/970"}],"wp:attachment":[{"href":"https:\/\/www.ub.edu\/creatio\/wp-json\/wp\/v2\/media?parent=969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}